Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(2):150-153. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0116

View: 2940 Download: 76 Web of Science: 3 Crossref: 2

Original Article

Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets

Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu

Clin Mol Hepatol. 2024;30(1):80-97. Published online December 7, 2023

DOI: https://doi.org/10.3350/cmh.2023.0343

View: 4457 Download: 206 Web of Science: 3 Crossref: 3

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Roles of the complement system in alcohol-induced liver disease

Yi Zhou, Guandou Yuan, Fudi Zhong, Songqing He

Clin Mol Hepatol. 2020;26(4):677-685. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0094

View: 7230 Download: 145 Web of Science: 13 Crossref: 14

Original Article

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Christian Mölleken, Maike Ahrens, Anders Schlosser, Julia Dietz, Martin Eisenacher, Helmut E. Meyer, Wolff Schmiegel, Uffe Holmskov, Christoph Sarrazin, Grith Lykke Sorensen, Barbara Sitek, Thilo Bracht

Clin Mol Hepatol. 2019;25(1):42-51. Published online November 19, 2018

DOI: https://doi.org/10.3350/cmh.2018.0029

View: 10685 Download: 124 Web of Science: 13 Crossref: 14

Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals

Yvelise Ferro, Ilaria Carè, Elisa Mazza, Francesco Provenzano, Carmela Colica, Carlo Torti, Stefano Romeo, Arturo Pujia, Tiziana Montalcini

Clin Mol Hepatol. 2017;23(3):249-259. Published online July 28, 2017

DOI: https://doi.org/10.3350/cmh.2017.0019

View: 13198 Download: 157 Web of Science: 19 Crossref: 21

Case Report

Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein

Jem Ma Ahn, Yong-Han Paik, Jun Hee Lee, Ju Yeon Cho, Won Sohn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo

Clin Mol Hepatol. 2015;21(4):393-397. Published online December 24, 2015

DOI: https://doi.org/10.3350/cmh.2015.21.4.393

View: 8838 Download: 78 Web of Science: 3 Crossref: 1

3

Optimal Cut-off Value of PIVKA-II for Diagnosis of Hepatocellular Carcinoma - Using ROC Curve -

Myong Jin Kim , Kang Woo Bae , Pyoung Ju Seo , In Kook Jeong , Jung Hyuk Kim , Bo Han Lee , Ki Tae Bang , Dong Woo Kim , Il Han Song

Clin Mol Hepatol. 2006;12(3):404-411. Published online January 1, 2000

View: 3804 Download: 74

Correspondence

Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”

Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu

Received April 16, 2024 Accepted April 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0266 [Epub ahead of print]

View: 661 Download: 22

Reply to Correspondence

Reply to correspondence on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Received April 30, 2024 Accepted April 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0320 [Epub ahead of print]

View: 713 Download: 44

1 |

Viewed By 4810	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4726	MAFLD: How is it different from NAFLD?
Viewed By 4633	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4377	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4290	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 116	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search